Antineoplastic peptides
View Patent ↗The present invention provides antineoplastic peptides of formula I, I R 1 R 2 N-CHX-CO-A-B-D-E-(G) S -K wherein R 1 , R 2 , X, A, B, D, E, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.
1. A method of treating a solid tumor in a mammal, comprising administering to the mammal an effective amount of a peptide, wherein the peptide is of the formula I:
(SEQ ID NO: 1)
(I)
Me 2 Val-Val-MeVal-Pro-Pto-NHC(CH 3 ) 3
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein the pharmaceutically acceptable salt is a hydrochloride salt.
3. The method of claim 1 , wherein the solid tumor is a tumor of the lung, breast, colon, prostate, bladder, rectum, or an endometrial tumor.
4. The method of claim 1 , wherein the peptide is of formula I is orally or parenterally administered to the mammal.
5. The method of claim 1 , wherein the peptide is of formula I is subcutaneously, intravenously, intramuscularly or intraperitoneally administered to the mammal.
6. The method of claim 4 , wherein the peptide is of formula I is orally administered at a dose of about 0.05 to 50 milligrams per kilogram of body weight.
7. The method of claim 4 , wherein the peptide of formula I is parenterally administered at a dose of about 0.01 to 20 milligrams per kilogram of body weight.
8. The method of claim 1 , wherein the peptide of formula I is in the in the form of a pharmaceutical composition.
9. The method of claim 1 , wherein the mammal is human.
10. A method of treating a hematological malignancy in a mammal, comprising administering to the mammal an effective amount of a peptide, wherein the peptide is of the formula I:
(SEQ ID NO: 1)
(I)
Me 2 Val-Val-MeVal-Pro-Pro-NHC(CH 3 ) 3
or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 wherein the pharmaceutically acceptable salt is a hydrochloride salt.
12. The method of claim 10 , wherein the hematological malignancy is a leukemia or a lymphoma.
13. The method of claim 10 , wherein the peptide of formula I is orally or parenterally administered to the mammal.
14. The method of claim 10 , wherein the peptide of formula I is subcutaneously, intravenously, intramusculary or intraperitoneally administered to the mammal.
15. The method of claim 13 , wherein the peptide of formula I is orally administered at a dose of about 0.05 to 50 milligrams per kilogram of body weight.
16. The method of claim 13 , wherein the peptide of formula I is parenterally administered at a dose of about 0.01 to 20 milligrams per kilogram of body weight.
17. The method of claim 10 wherein the peptide of formula I is in the in the form of a pharmaceutical composition.
18. The method of claim 10 , wherein the mammal is human.